AUTHORS
Efstathios Kastritis, MD, Meletios-Athanasios (Thanos) C. Dimopoulos, MD2, Maria Gavriatopoulou, MD3, Alexander Grunenberg, MD4, Matthias Zingerle, MD5, Sebastian Böttcher, MD6, Tobias Gaska, MD7, Holger Hebart, MD8, Michael Gärtner, PhD9, Volkmar Böhme, MD10, Lisa Pleyer11, Philipp Staber, MD, PhD12, Johannes Mohm, MD13, Bjoern Schoettker, PhD14, Ralf Ulrich Trappe15, Ursula vehling-kaiser, MD16, Eva Hoster, PhD17, Katja Gutmair, PhD18, Falko Fend, MD19, Jana Berthold20, Dajana Kaszynski21, Christian Buske, MD22
AFFILIATIONS
1 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4 University Hospital of Ulm, Ulm, Germany
5 Munich-Pasing MVZ GmbH, Munich, Germany
6 Rostock University Medical Center, Rostock, Germany
7 Bruederkrankenhaus Paderborn, Paderborn, Germany
8 Stauferklinikum, Mutlangen, Mutlangen, Germany
9 Oncology Outpatient Center, Hannover, Greece
10 Practice for Oncology, Hamburg, Germany
11 Paracelsus Medical University Hospital, Salzburg, Austria
12 Medical University Vienna, Vienna, Austria
13 Practice for Haematology and Oncology, Practice for Hematology and Oncology, Dresden, Germany, Germany
14 Joint practice for Haematology and Internal Oncology, Wuerzburg, Germany
15 DIAKO Ev. Diakonie-Krankenhaus, Bremen, Germany
16 Oncological Practice, Landshut, Germany
17 Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), LMU Medizin, Ludwig-Maximilians Universität München, Munich, Germany
18 Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), LMU Medizin, Ludwig-Maximilians Universität München, Munich, Germany
19 University of Tübingen, Tuebingen, Germany
20 Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany
21 Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany
22 Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany, Ulm, Greece, University Hospital of Ulm, Ulm, Germany
ABSTRACT
Background: In Waldenström’s macroglobulinemia (WM) treatment with covalent BTK inhibitors (cBTKi) is one of the standards of care based on their efficacy and favorable toxicity profile. However, cBTKis are less effective in patients (pts) with MYD88mut/CXCR4mut or unmutated MYD88. The proteasome inhibitor (PI) bortezomib is active in WM, but is limited by its potential neurotoxicity. Phase II data indicated that the 2nd-generation PI carfilzomib can overcome the impact of MYD88 and CXCR4 genotypes while being a neuropathy-sparing option. Based on the hypothesis that addition of carfilzomib to ibrutinib will increase the efficacy compared to Ibrutinib alone, independently of the MYD88/CXCR4 mutational status, the European Consortium for Waldenström’s Macroglobulinemia initiated an academic randomized multicenter trial comparing Carfilzomib/Ibrutinib to single agent Ibrutinib.
Methods: CZAR-1 (NCT 04263480) is an open label phase II study that randomized 1:1 de novo and relapsed/refractory WM pts requiring therapy to either ibrutinib with carfilzomib (Ibr/Carf) or ibrutinib monotherapy (Ibr) stratified according to MYD88 and CXCR4 status and prior therapy (0 vs ≥1). Pts in both arms received continuous Ibr 420 mg/day until disease progression or intolerance; pts in the experimental arm additionally received carfilzomib in 28-day cycles (20 mg/m2 on day 1 of cycle (C) 1 and 70 mg/m2 days 8, 15 and on days 1,8 & 15 of C2-12, followed by 70 mg/m2 on days 1 &15 for C13-24). The primary end point of the study was CR/VGPR probability after 12 months from randomization and the primary analysis compared the trial arms on a one-sided 10% significance level. Secondary endpoints included overall and best response probabilities, time to first and to best response, time to treatment failure, remission duration, PFS, cause specific survival, OS, safety, and QoL. Response was assessed according to IWWM-6 criteria.
Results: 100 pts were randomized and received at least one dose of study treatment (49 Ibr/Carf and 51 Ibr); median age was 71 years (46-90) in Ibr/Carf and 73 (49-88) in Ibr arm; 68.5% and 72.5% were >65 years and 12% in each group were >80 years, respectively. At screening, anemia (<10 gr/dl) was present in 49% and 65%; 37% and 41% had B-symptoms, 12% and 8% peripheral neuropathy, respectively. Median BM infiltration was 70%; 96% had MYD88L265P and 31% had CXCR4 mutations in both groups. 76% and 82% were treatment naïve; among pre-treated pts the median number of prior lines was 1 (range 1-3). On intention to treat at 12 months landmark 18/49 (36.7%) vs 2/51 (3.9%) pts achieved CR/VGPR with Ibr/Carf vs Ibr (p<0.001 two-sided), confirming the primary trial hypothesis. As best response, 24 ( 49%) pts achieved a CR/VGPR with Ibr/Carf (and additional 24 (49%) a PR) vs 5 (10%) in the Ibr arm (and 31 (61%) a PR). There was a substantial difference in CR/VGPR probabilities at 12-months in favor of Ibr/Carf in both treatment naïve (36.8% vs 4.9%) and relapsed/refractory (36.4% vs 0%) pts. Ibr/Carf was superior to Ibr in both CXCR4WT (CR/VGPR in 38.2% vs 6% in MYD88mut/CXCR4WT) and MYD88mut/CXCR4mut pts (in 33.3% vs 0%), respectively. There was no significant difference in the PFS and OS between the two treatment arms.
Seventy-four pts had at least one ≥Gr3 AE (39 with Ibr/Carf and 33 with Ibr). The most common ≥Gr3 AEs were hypertension (26.5% vs 6%), fatigue (14% vs 2%), dyspnea (8% vs 2%), AF (8% vs 2%), thrombocytopenia (8% vs 2%), urinary tract (8% vs 4%) and lower respiratory tract infection (6% vs 6%), arthralgia (4% vs 7%), septic shock (6% vs 2%). One case of Gr3 peripheral neuropathy occurred in the Ibr/Carf arm. One secondary transformation occurred in the Ibr arm. Twelve patients have died, 7 in the Ibr/Carf and 5 in the Ibr arm.
Conclusion: this is the first randomized study to evaluate the addition of a PI to a cBTKi in WM. Adding carfilzomib to ibrutinib significantly increased deep response probabilities independently of CXCR4 mutations. Despite higher toxicity, Ibr/Carf could provide a chemotherapy-free option with meaningful clinical benefit, supporting its consideration for pts requiring rapid and deep remissions.
DISCLOSURES
Efstathios Kastritis, MD: Genesis Pharma - Honoraria; GSK - Honoraria; Pfizer - Honoraria; Johnson and Johnson - Honoraria; Abbvie - Honoraria; Pfizer - Research Funding; Johnson and Johnson - Research Funding; GSK - Research Funding; Abbvie - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)